On July 29, 2025, during a joint press conference, the U.S. Food and Drug Administration (FDA or the Agency) recommended to the Drug Enforcement Administration (DEA) to classify 7-hydroxymitragynine (7-OH) as a Schedule I...more
8/13/2025
/ Administrative Procedure Act ,
Controlled Substances ,
Controlled Substances Act ,
DEA ,
Due Process ,
Food and Drug Administration (FDA) ,
Joint Statements ,
Judicial Review ,
Opioid ,
Public Comment ,
Public Health ,
Rulemaking Process ,
Schedule I Drugs